<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Orthop</journal-id><journal-id journal-id-type="publisher-id">ORT</journal-id><journal-title-group><journal-title>Acta Orthopaedica</journal-title></journal-title-group><issn pub-type="ppub">1745-3674</issn><issn pub-type="epub">1745-3682</issn><publisher><publisher-name>Informa Healthcare</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19626470</article-id><article-id pub-id-type="publisher-id">SORT_A_402710_O</article-id><article-id pub-id-type="doi">10.3109/17453670903025378</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Incidence of genetic polymorphisms involved in lipid metabolism among Chinese patients with osteonecrosis of the femoral head</article-title></title-group><contrib-group><contrib id="a1" contrib-type="author"><name><surname>He</surname><given-names>Wei</given-names></name></contrib><contrib id="a2" contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Keda</given-names></name></contrib><aff id="AF0001"><institution>Department of Orthopaedics, First Affiliated Hospital of Guangzhou, University of Traditional Chinese Medicine, BaiYun District</institution><addr-line>Guangzhou</addr-line><country>China</country></aff></contrib-group><author-notes><corresp>Correspondence LIK: <email>kodar777@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>05</day><month>6</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>01</day><month>6</month><year>2009</year></pub-date><volume>80</volume><issue>3</issue><fpage>325</fpage><lpage>329</lpage><history><date date-type="received"><day>23</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2009</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Nordic Orthopedic Federation</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited.</license-p></license></permissions><abstract><p><bold>Background and purpose</bold> Corticosteroid treatment is associated with osteonecrosis of the femoral head (ON) in certain patients. The degree of drug sensitivity in general is governed by genetic variation between individuals. We investigated the relationship between ON and the presence of different alleles of the cytochrome P450 gene <italic>(CYP3A4)</italic>, the product of which metabolizes corticosteroids, and of the P-glycoprotein (P-gp) gene <italic>(ABCB1),</italic> the product of which modulates cellular uptake of corticosteroids, to determine whether patients with certain alleles may be at higher risk of ON after corticosteroid treatment.</p><p><bold>Methods</bold> We studied 31 patients from Guangdong, China who were both treated with corticosteroid therapy and developed ON, and 17 corticosteroid-therapy patients without ON. Patient DNA was screened for known polymorphisms in the <italic>CYP3A4</italic> gene <italic>(CYP3A4*4, CYP3A4*5, CYP3A4*6)</italic> and the P-gp gene <italic>ABCB1</italic> (mutations C3435T, G2677T/A).</p><p><bold>Results</bold> The majority (20/31) of the corticosteroid-treated patients who developed ON were heterozygous for <italic>ABCB1,</italic> whereas only 3/17 without ON were heterozygous. Statistical significance was observed between the ON and the control groups for the <italic>ABCB1</italic> G2677T/A polymorphism. Analysis of haplotypic frequencies indicated significant linkage disequilibrium between the two <italic>ABCB1</italic> polymorphisms, C3435T and G2677T/A (D' = 0.034). No <italic>CYP3A4</italic> polymorphisms were detected in any of the patients.</p><p><bold>Interpretation</bold> Patients carrying an <italic>ABCB1</italic> polymorphism had a higher risk of having corticosteroid-associated ON than those with wild-type genotypes. This statistically significant association conflicts with previous studies, possibly due to different sampling methods. Knowing which genetic backgrounds are most strongly associated with corticosteroid-associated ON provides a method of screening for patients who are most at risk of developing ON.</p></abstract></article-meta></front><body><sec id="intro"><title>Introduction</title><p>Non-traumatic osteonecrosis (ON) of the femoral head is the gradual destruction of the femur head due to loss of blood flow and osteocyte death; it is characterized by disruption of intravascular blood flow, cellular toxicity, and impaired differentiation of mesenchymal cells, ultimately leading to bone death (<xref ref-type="bibr" rid="CIT0012">Lieberman et al. 2003</xref>). Both arterial circulation&#x02014;compromised by femoral neck fracture or arterial thrombosis/apoptosis from systemic diseases (e.g. lupus erythematous and hemoglobinopathies) (<xref ref-type="bibr" rid="CIT0013">Mankin 1992</xref>)&#x02014;and high intraosseous pressure, resulting from prolonged corticosteroid administration or ethanol abuse, obstruct blood flow in the femoral head and increase marrow cellularity and fat (<xref ref-type="bibr" rid="CIT0003">Drescher et al. 2006</xref>). Although discreet pathogenetic mechanisms have yet to be identified in ON, corticosteroid and ethanol abuse have a profound effect on physiological bone turnover and oxygenation, and are associated with more than 90% of all osteonecrosis cases (<xref ref-type="bibr" rid="CIT0019">Schroer 1994</xref>). The varying frequency and the clinical course of ON development in patients taking large doses of corticosteroids have been increasingly attributed (in part) to the presence of single nucleotide polymorphisms (SNPs) in the DNA sequences of genes encoding metabolic enzymes such as P-glycoprotein (P-gp) and cytochrome P450 (<xref ref-type="bibr" rid="CIT0002">Asano et al. 2003b</xref>).</p><p>P-gp is an ATP-dependent membrane efflux pump that maintains intracellular drug and xenobiotic concentrations below cytotoxic levels (<xref ref-type="bibr" rid="CIT0025">Tsuji et al. 1997</xref>). P-gp is encoded by the multidrug-resistance 1 <italic>(MDR1)</italic> gene, also known as the ABC transporter B1 <italic>(ABCB1)</italic> gene (<xref ref-type="bibr" rid="CIT0018">Sakaeda et al. 2002</xref>). Corticosteroids are well established to be a P-gp substrate (<xref ref-type="bibr" rid="CIT0016">Saeki et al. 1993</xref>). Numerous SNPs in the <italic>ABCB1</italic> gene have been identified, two of which (C3435T and G2677T/A) have been widely studied and associated with functional changes in P-gp expression or activity (<xref ref-type="bibr" rid="CIT0023">Tanabe et al. 2001</xref>). Interindividual variation in <italic>ABCB1</italic> may consequently modify P-gp expression and the pharmacokinetics of corticosteroids and metabolites, contributing to the cortisol sensitivity of certain individuals and increasing the risk of developing ON. A prognostic relationship between the <italic>ABCB1</italic> C3435T and G2677T/A polymorphisms and cortisol-associated ON development has recently been established (<xref ref-type="bibr" rid="CIT0023">Tanabe et al. 2001</xref>, <xref ref-type="bibr" rid="CIT0001">Asano et al. 2003a</xref>).</p><p>The cytochrome P450 family is a group of enzymes involved in the oxidative and reductive metabolism of almost all lipid-soluble medicines. The product of the cytochrome P450 gene, <italic>CYP3A4</italic>, is considered to be the main cytochrome responsible for steroid metabolism (<xref ref-type="bibr" rid="CIT0009">Kitada et al. 1987</xref>). <italic>CYP3A4</italic> also exhibits an approximate 40-fold degree of interindividual polymorphic variation, including <italic>CYP3A*1-*5</italic> alleles, which have been associated with reduced activity of cytochrome P450 (<xref ref-type="bibr" rid="CIT0007">Hsieh et al. 2001</xref>), a prognostic factor associated with increased incidence of ON and with the extent of necrotic infiltration in a rabbit model (<xref ref-type="bibr" rid="CIT0014">Masada et al. 2008</xref>).</p><p>The objective of the present study was to assess the incidence of <italic>ABCB1</italic> C3435T and G2677T/A genotypes, and of polymorphisms of <italic>CYP3A4 (CYP3A4*4, CYP3A4*5, CYP3A4*6)</italic> in a multicenter, randomized post-corticosteroid therapy patient cohort with or without corticosteroid-associated ON. Clarification of the prevalence of specific genetic polymorphisms in corticosteroid-associated ON patients will encourage greater acknowledgement of the prophylactic measures potentially available through individualized corticosteroid administration.</p></sec><sec id="S002" sec-type="methods"><title>Patients and methods</title><sec id="S2001"><title>Study subjects</title><p>The study protocol was approved by the local institutional and administrative review board of the First Affiliated Hospital of Guangzhou TCM University, and all patients provided written informed consent before participation. All were from the Guangdong Province of China. 31 consecutive randomized patients who were treated with corticosteroid therapy and had documented ON, and 17 consecutive corticosteroid-therapy patients without ON were included in this study. The patients were diagnosed with ON in accordance with the criteria prescribed by <xref ref-type="bibr" rid="CIT0022">Sugano et al. (2002)</xref>. Patient history of corticosteroid use, exposure to hyperbaric conditions, known systemic and other concomitant diseases, and hemoglobinopathies were obtained by review of patient charts. Corticosteroid-associated ON patients were defined as those who took continuous corticosteroid medication for at least 2 months before physical and radiological examination of the hips. Patients with ON prior to corticosteroid administration or those with a history of ethanol abuse were excluded.</p></sec><sec id="S2002"><title>Sequence analysis of the CYP3A4*4, CYP3A4*5, and CYP3A4*6 polymorphisms and the ABCB1 C3435T and G2677T/A polymorphisms</title><p><italic>CYP3A4*4, CYP3A4*5</italic>, and <italic>CYP3A4*6</italic> polymorphisms and <italic>ABCB1</italic> C3435T and G2677T/A polymorphisms were determined by sequencing polymerase chain reaction (PCR) products of the polymorphic regions from each patient, as previously described (<xref ref-type="bibr" rid="CIT0001">Asano et al. 2003a</xref>). Briefly, genomic DNA for PCR was extracted from peripheral blood samples using the DNeasy Tissue Kit (Qiagen Gmbh, Hilden, Germany) following the manufacturer's instructions. Oligonucleotide primers for PCR amplification were derived from known sequences (GenBank accession number M29445 for C3435T and M29440 for G2677T/A). The sequences for the CYP primers were: forward 5'-CAC ATT TTC TAC AAC CAT GGA GAC C-3' and reverse 5'-TTT TAT ACC TGT CCC CAC CAG ATT C-3' for <italic>CYP3A4*4</italic>; forward 5'-TGT TGC ATG CAT AGA GGA AGG ATG G-3' and reverse 5'-GAT GAC AGG GTT TGT GAC AGG GG-3' for <italic>CYP3A4*5</italic>; and forward 5'-GAG CCA TAT TCT CAG AAG GGA GAT CAA G-3' and reverse 5'-CAA ACA TGT GTC GTT CTG CTA TGT GG-3' for <italic>CYP3A4*6.</italic> The sequences for the <italic>ABCB1</italic> primers were: forward 5'-TTC AGC TGC TTG ATG GCA AA-3' and reverse 5'-AGG CAG TGA CTC GAT GAA GG-3' for C3435T; and forward 5'-CAG GCT TGC TGT AAT TAC CC-3' and reverse 5'-TAG TTT GAC TCA CCT TCC CA-3' for G2677T/A. The PCR amplification program consisted of an initial denaturation step at 94&#x000b0;C for 5 min, followed by 35 cycles of denaturation at 94&#x000b0;C for 1 min, annealing at 58&#x000b0;C for 1 min and extension at 72&#x000b0;C for 1 min, and a final extension at 72&#x000b0;C for 5 min. The resulting PCR fragments were then purified and sequenced using BigDye Terminator sequencing reactions in an automated DNA sequencer (ABI 3730; Applied Biosystems).</p></sec><sec id="S2003"><title>Statistics</title><p>Post-randomization clinical data and patient characteristics were stratified in terms of post-cortisol-associated ON patients and post-cortisol patients without ON. Statistical analysis of polymorphisms in the <italic>ABCB1</italic> gene was conducted using the chi-square test or Fisher's exact test. Haplotype frequencies were estimated using pairwise linkage disequilibrium coefficients calculated from estimated haplotype frequencies of C3545T and G2677T/A as previously described (<xref ref-type="bibr" rid="CIT0001">Asano et al. 2003a</xref>).</p></sec></sec><sec id="S003"><title>Results</title><sec id="S2004"><title>Patient characteristics</title><p>The distribution of sex and age between the ON group (31 patients) and the control group (17 patients) was similar, with 14 females and 17 males with a median age of 32 (12&#x02013;58) years in the ON group, and 9 females and 8 males with a median age of 30 (19&#x02013;59) years in the control group. Patients were admitted for a variety of conditions requiring corticosteroid therapy. In the ON group, the patients were admitted for trauma (4), psoriasis (2), rubeola (2), renal disease (5), mixed connective tissue disease (3), systemic lupus erythematosus (7), atopy (2), rheumatoid arthritis (1), renal transplantation (1), asthma (1), mycotic opthalmia (1), aplastic anaemia (1), or chronic pharyngitis (1). In the control group, patients were admitted for renal disease (10) or systemic lupus erythematosus (7).</p></sec><sec id="S2005"><title>Incidence of ABCB1 C3435T and G2677T/A polymorphisms</title><p>Of the 31 ON patients who were genotyped for the <italic>ABCB1</italic> C3435T polymorphism, 24 had the wild-type CC genotype, 7 had the heterozygous CT phenotype, and none had the homozygous TT phenotype. Of the 17 control patients, 14 had CC, 3 had CT, and none had TT.</p><p>Of the 31 ON patients who were genotyped for the <italic>ABCB1</italic> G2677T/A polymorphism, 18 had the wild-type GG genotype, 9 had the heterozygous GT phenotype, 4 had the heterozygous GA phenotype, and none had any of the remaining possible polymorphic phenotypes. Of the 17 control patients, all 17 had the wild-type GG phenotype.</p><p>In the ON group, 20/31 patients carried one copy of a polymorphic allele of either C3435T (n = 7) or G2677T/A (n = 13), and 13 of all 31 patients carrying <italic>ABCB1</italic> polymorphic alleles developed corticosteroid-associated ON. 24 patients homozygous for the wild-type 3435CC sequence and 18 patients homozygous for the 2677GG polymorphism developed ON subsequent to corticosteroid administration.</p><p>There was significant difference between the ON and control group for SNPs in the ABCB1 G2677T/A polymorphism (p = 0.002, <xref ref-type="table" rid="T0001">Table 1</xref>). Analysis of haplotypic frequencies by Fisher's exact test indicated significant linkage disequilibrium between C3435T and G2677T/A (D' = 0.03), which is in agreement with the results of <xref ref-type="bibr" rid="CIT0001">Asano et al. (2003a)</xref> (<xref ref-type="table" rid="T0002">Table 2</xref>).</p><table-wrap id="T0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Single nucleotide polymorphisms (SNPs) of ABCB1 exon 26 (C3435T) and exon 21 (G2677T/A) (n = 48)</p></caption><table frame="hsides" rules="groups" id="table1"><thead><tr><th rowspan="1" colspan="1">SNPs</th><th rowspan="1" colspan="1">SNP ON</th><th rowspan="1" colspan="1">C3435T Control</th><th rowspan="1" colspan="1">p-value <bold><sup>a</sup></bold></th><th rowspan="1" colspan="1">SNP ON</th><th rowspan="1" colspan="1">G2677T/A Control</th><th rowspan="1" colspan="1">p-value <bold><sup>a</sup></bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1.0</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn><p><bold><sup>a</sup></bold> Fisher's exact test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Chi-squared test of independence for single nucleotide polymorphisms (SNPs) of ABCB1: C3435T and G2677T/A (n = 48)</p></caption><table frame="hsides" rules="groups" id="table2"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">G2677T/A SNPs</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1">C3435T SNPs</th><th rowspan="1" colspan="1">No</th><th rowspan="1" colspan="1">Yes</th><th rowspan="1" colspan="1">p-value <bold><sup>a</sup></bold></th><th rowspan="1" colspan="1">D' <bold><sup>b</sup></bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">0.4</td><td rowspan="1" colspan="1">0.03</td></tr><tr><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold><sup>a</sup></bold> Fisher's exact test.</p></fn><fn><p><bold><sup>b</sup></bold> Linkage disequilibrium coefficient (D')</p></fn></table-wrap-foot></table-wrap></sec><sec id="S2006"><title>Incidence of CYP3A4*4, CYP3A4*5, and CYP3A4*6 polymorphisms</title><p>Using sequence analysis, no <italic>CYP3A4*4, CYP3A4*5</italic>, or <italic>CYP3A4*6</italic> polymorphisms were detected. These findings were discordant in part with the previously published results of <xref ref-type="bibr" rid="CIT0002">Asano et al. (2003b)</xref>.</p></sec></sec><sec id="S004"><title>Discussion</title><p>Our results indicate a statistically significant difference between the ON and control groups regarding the ABCB1 C3435T and G2677T/A SNPs, suggesting a positive association between these genetic polymorphisms and the susceptibility of corticosteroid-associated ON. It is interesting that this result conflicts with the observation of <xref ref-type="bibr" rid="CIT0001">Asano et al. (2003a)</xref>, in which the C3435T (3435TT genotype, but not 3435CT genotype) and G2677T/A (2677TT, 2677TA, and 2677AA genotypes) SNPs were associated with a reduced risk of corticosteroid-associated ON. Ethnic background should probably be considered to be the primary cause of this diversity. To date, 28 SNPs in the <italic>ABCB1</italic> gene have been reported at 27 positions in Caucasians and Africans (<xref ref-type="bibr" rid="CIT0006">Hoffmeyer et al. 2000</xref>, <xref ref-type="bibr" rid="CIT0008">Kim et al. 2001</xref>, <xref ref-type="bibr" rid="CIT0020">Siegmund et al. 2002</xref>), of which only a few C3435T SNPs were associated with P-gp expression, function, or increased plasma concentration. Other studies have also found a diversified allelic frequency in the wobble SNP in C3435T, with Caucasians and Japanese showing frequencies different from those of Africans (<xref ref-type="bibr" rid="CIT0016">Saeki et al. 1993</xref>). The involvement of the 3435T variant allele has been reported previously by <xref ref-type="bibr" rid="CIT0020">Siegmund et al. (2002)</xref>, in which healthy Japanese patients harboring the allele had lower serum concentrations of digoxin after a single injection as compared to wild-type subjects. Other studies have shown conflicting results, with a lack of genotype-phenotype correlation between C3435T SNPs and cyclosporine efficacy in renal transplantation patients, indicating that C3435T is not the only polymorphism involved in P-gp expression (<xref ref-type="bibr" rid="CIT0017">Sakaeda et al. 2001</xref>). However, recent studies have shown that carriers of the <italic>ABCB1</italic> 3435T allele have enhanced oral clearance of cyclosporine compared to Caucasian individuals with the 3435CC genotype (<xref ref-type="bibr" rid="CIT0027">von Ahsen et al. 2001</xref>), and they have reduced expression of intestinal CYP3A4 mRNA (<xref ref-type="bibr" rid="CIT0029">Yates et al. 2003</xref>).</p><p>A statistically significant linkage disequilibrium between the C3435T and G2677T/A SNPs was identified in both this study and that of <xref ref-type="bibr" rid="CIT0001">Asano et al. (2003a)</xref>, corroborating the involvement of the <italic>ABCB1</italic> C3435T and G2677T/A SNPs in the pathogenesis of corticosteroid-associated ON. However, whether the involvement is a risk factor for or against corticosteroid-associated ON remains to be determined. Although the physiological role of P-gp remains elusive, interindividual expression of the highly polymorphic ABCB1 gene is likely to contribute to variability in the pharmacokinetics and pharmacodynamics of many drugs (<xref ref-type="bibr" rid="CIT0016">Saeki et al. 1993</xref>) in addition to increased susceptibility to cancer (<xref ref-type="bibr" rid="CIT0021">Siegsmund et al. 2002</xref>). C3435T and G2677T/A SNPs do not involve amino acid substitution and do not functionally influence P-gp expression directly (<xref ref-type="bibr" rid="CIT0020">Siegmund et al. 2002</xref>). Thus, their functional significance may be that they are involved in post-transcriptional mRNA processing and affect the quality or quantity of P-gp protein expression.</p><p>The frequencies of the C3435T alleles in our test groups were much different from those reported for normal healthy Han Chinese populations (reviewed in <xref ref-type="bibr" rid="CIT0011">Li et al. 2006</xref>). Previous studies of Han Chinese populations from Singapore, southwest China, and Northern China showed a typical Hardy-Weinberg distribution of genotypes. In contrast, our data show a low frequency of T alleles. It is likely that our results may have been affected by both sampling error due to low sample size and by the fact that the samples came from unhealthy individuals. Similar conclusions may be drawn regarding the G2677T/A allele, based on its strong linkage to the C3435T allele.</p><p>The <italic>CYP3A</italic> subfamily of cytochrome P450 proteins are found most abundantly in the liver and intestine, accounting for approximately 95% of the <italic>CYP3A</italic> mRNA-pool in Caucasians (<xref ref-type="bibr" rid="CIT0010">Koch et al. 2002</xref>). The protein products of <italic>CYP3A4</italic> and <italic>CYP3A5</italic> are preferentially involved in the catalysis of exogenous and endogenous compounds. Contrary to the expected SNP variability of <italic>CYP3A</italic> genes (<xref ref-type="bibr" rid="CIT0007">Hsieh et al. 2001</xref>), all of the subjects in our patient cohort were homozygous wild-types. Certain alleles of these genes <italic>(CYP3A4*4</italic> and <italic>CYP3A4*5)</italic> are associated with clinically relevant changes in drug clearance (<xref ref-type="bibr" rid="CIT0005">Felix et al. 1998</xref>, <xref ref-type="bibr" rid="CIT0024">Thervet et al. 2003</xref>). Our study design did not allow for measurement of the systemic clearance of <italic>CYP3A</italic> substrate drugs in relation to development of ON; however, recent studies have shown that the CYP alleles we examined are rare in the Chinese population (<xref ref-type="bibr" rid="CIT0007">Hsieh et al. 2001</xref>, <xref ref-type="bibr" rid="CIT0028">Wen et al. 2004</xref>). Instead, the Chinese population contains a number of novel CYP mutations that are rare in other populations (<xref ref-type="bibr" rid="CIT0004">Du et al. 2006</xref>). We suggest evaluation of the roles of other <italic>CYP3A</italic> genes in relation to ON and control groups, with clearly identifying the substrate regiments of the gene products in the future.</p><p>Interestingly, all the patients who did not develop ON had either kidney disease or lupus. Both kidney disease (<xref ref-type="bibr" rid="CIT0015">Naud et al. 2008</xref>) and lupus (<xref ref-type="bibr" rid="CIT0026">Tsujimura et al. 2005</xref>) can increase P-gp activity. It is possible that these diseases counteracted any genetic influences on corticosteroid clearance by upregulating P-gp expression, thus providing protection against ON.</p></sec></body><back><ack><title>Acknowledgements</title><p>HEW wrote the study protocol and did the loading tests. LIK wrote the article and did the interpretation and statistical analysis of the data.</p><p>This study was supported by the Chinese Postdoctoral Science Foundation, grant 29970410234, and the National Nature Science Foundation, grant 30672700.</p><p>No competing interests declared.</p></ack><ref-list><ref id="CIT0001"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>KA</given-names></name><name><surname>Fujioka</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Sugioka</surname><given-names>N</given-names></name><etal/></person-group><article-title>ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation.</article-title><source>Pharmacogenetics</source><year>2003a</year><volume>13</volume><fpage>675</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">14583680</pub-id></element-citation></ref><ref id="CIT0002"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>KA</given-names></name><name><surname>Fujioka</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name><name><surname>Satomi</surname><given-names>Y</given-names></name><name><surname>Nishino</surname><given-names>H</given-names></name><etal/></person-group><article-title>Genetic analysis of steroid-induced osteonecrosis of the femoral head.</article-title><source>J Orthop Sci</source><year>2003b</year><volume>8</volume><fpage>329</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">12768474</pub-id></element-citation></ref><ref id="CIT0003"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drescher</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Lundgaard</surname><given-names>A</given-names></name><name><surname>Bunger</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>ES</given-names></name></person-group><article-title>Endothelin-1-induced femoral head epiphyseal artery constriction is enhanced by long-term corticosteroid treatment.</article-title><source>J Bone Joint Surg (Am) (Suppl 3)</source><year>2006</year><volume>88</volume><fpage>173</fpage><lpage>9</lpage></element-citation></ref><ref id="CIT0004"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Xing</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Shu</surname><given-names>A</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.</article-title><source>Pharmacogenomics</source><year>2006</year><volume>7</volume><fpage>831</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16981844</pub-id></element-citation></ref><ref id="CIT0005"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felix</surname><given-names>CA</given-names></name><name><surname>Walker</surname><given-names>AH</given-names></name><name><surname>Lange</surname><given-names>BJ</given-names></name><name><surname>Williams</surname><given-names>TM</given-names></name><name><surname>Winick</surname><given-names>NJ</given-names></name><name><surname>Cheung</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Association of CYP3A4 genotype with treatment-related leukemia.</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>13176</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">9789061</pub-id></element-citation></ref><ref id="CIT0006"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmeyer</surname><given-names>S</given-names></name><name><surname>Burk</surname><given-names>O</given-names></name><name><surname>von Richter</surname><given-names>O</given-names></name><name><surname>Arnold</surname><given-names>HP</given-names></name><name><surname>Brockmoller</surname><given-names>J</given-names></name><name><surname>Johne</surname><given-names>A</given-names></name><etal/></person-group><article-title>Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.</article-title><source>Proc Natl Acad Sci U S A</source><year>2000</year><volume>97</volume><fpage>3473</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10716719</pub-id></element-citation></ref><ref id="CIT0007"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>KP</given-names></name><name><surname>Lin</surname><given-names>YY</given-names></name><name><surname>Cheng</surname><given-names>CL</given-names></name><name><surname>Lai</surname><given-names>ML</given-names></name><name><surname>Lin</surname><given-names>MS</given-names></name><name><surname>Siest</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Novel mutations of CYP3A4 in Chinese.</article-title><source>Drug Metab Dispos</source><year>2001</year><volume>29</volume><fpage>268</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">11181494</pub-id></element-citation></ref><ref id="CIT0008"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>RB</given-names></name><name><surname>Leake</surname><given-names>BF</given-names></name><name><surname>Choo</surname><given-names>EF</given-names></name><name><surname>Dresser</surname><given-names>GK</given-names></name><name><surname>Kubba</surname><given-names>SV</given-names></name><name><surname>Schwarz</surname><given-names>UI</given-names></name><etal/></person-group><article-title>Identification of functionally variant MDR1 alleles among European Americans and African Americans.</article-title><source>Clin Pharmacol Ther</source><year>2001</year><volume>70</volume><fpage>189</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">11503014</pub-id></element-citation></ref><ref id="CIT0009"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitada</surname><given-names>M</given-names></name><name><surname>Kamataki</surname><given-names>T</given-names></name><name><surname>Itahashi</surname><given-names>K</given-names></name><name><surname>Rikihisa</surname><given-names>T</given-names></name><name><surname>Kanakubo</surname><given-names>Y.</given-names></name></person-group><article-title>Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations.</article-title><source>Biochem Pharmacol</source><year>1987</year><volume>36</volume><fpage>453</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">3493777</pub-id></element-citation></ref><ref id="CIT0010"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>I</given-names></name><name><surname>Weil</surname><given-names>R</given-names></name><name><surname>Wolbold</surname><given-names>R</given-names></name><name><surname>Brockmoller</surname><given-names>J</given-names></name><name><surname>Hustert</surname><given-names>E</given-names></name><name><surname>Burk</surname><given-names>O</given-names></name><etal/></person-group><article-title>Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.</article-title><source>Drug Metab Dispos</source><year>2002</year><volume>30</volume><fpage>1108</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">12228187</pub-id></element-citation></ref><ref id="CIT0011"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name></person-group><article-title>Distribution of the functional MDR1 C3435T polymorphism in the Han population of China.</article-title><source>Swiss Med Wkly</source><year>2006</year><volume>136</volume><fpage>377</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">16847760</pub-id></element-citation></ref><ref id="CIT0012"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>JR</given-names></name><name><surname>Berry</surname><given-names>DJ</given-names></name><name><surname>Mont</surname><given-names>MA</given-names></name><name><surname>Aaron</surname><given-names>RK</given-names></name><name><surname>Callaghan</surname><given-names>JJ</given-names></name><name><surname>Rajadhyaksha</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Osteonecrosis of the hip: management in the 21st century.</article-title><source>Instr Course Lect</source><year>2003</year><volume>52</volume><fpage>337</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">12690862</pub-id></element-citation></ref><ref id="CIT0013"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mankin</surname><given-names>HJ.</given-names></name></person-group><article-title>Nontraumatic necrosis of bone (osteonecrosis).</article-title><source>N Engl J Med</source><year>1992</year><volume>326</volume><fpage>1473</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1574093</pub-id></element-citation></ref><ref id="CIT0014"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masada</surname><given-names>T</given-names></name><name><surname>Iwakiri</surname><given-names>K</given-names></name><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Kaneshiro</surname><given-names>Y</given-names></name><name><surname>Iwaki</surname><given-names>H</given-names></name><name><surname>Ohashi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Increased hepatic cytochrome P4503A activity decreases the risk of developing steroid-induced osteonecrosis in a rabbit model.</article-title><source>J Orthop Res</source><year>2008</year><volume>26</volume><fpage>91</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17787012</pub-id></element-citation></ref><ref id="CIT0015"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naud</surname><given-names>J</given-names></name><name><surname>Michaud</surname><given-names>J</given-names></name><name><surname>Leblond</surname><given-names>FA</given-names></name><name><surname>Lefrancois</surname><given-names>S</given-names></name><name><surname>Bonnardeaux</surname><given-names>A</given-names></name><name><surname>Pichette</surname><given-names>V.</given-names></name></person-group><article-title>Effects of chronic renal failure on liver drug transporters.</article-title><source>Drug Metab Dispos</source><year>2008</year><volume>36</volume><fpage>124</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17940133</pub-id></element-citation></ref><ref id="CIT0016"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeki</surname><given-names>T</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name><name><surname>Tanigawara</surname><given-names>Y</given-names></name><name><surname>Hori</surname><given-names>R</given-names></name><name><surname>Komano</surname><given-names>T.</given-names></name></person-group><article-title>Human P-glycoprotein transports cyclosporin A and FK506.</article-title><source>J Biol Chem</source><year>1993</year><volume>268</volume><fpage>6077</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">7681059</pub-id></element-citation></ref><ref id="CIT0017"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaeda</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Horinouchi</surname><given-names>M</given-names></name><name><surname>Kakumoto</surname><given-names>M</given-names></name><name><surname>Ohmoto</surname><given-names>N</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><etal/></person-group><article-title>MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.</article-title><source>Pharm Res</source><year>2001</year><volume>18</volume><fpage>1400</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11697464</pub-id></element-citation></ref><ref id="CIT0018"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaeda</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Okumura</surname><given-names>K.</given-names></name></person-group><article-title>MDR1 genotype-related pharmacokinetics and pharmacodynamics.</article-title><source>Biol Pharm Bull</source><year>2002</year><volume>25</volume><fpage>1391</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">12419946</pub-id></element-citation></ref><ref id="CIT0019"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroer</surname><given-names>WC.</given-names></name></person-group><article-title>Current concepts on the pathogenesis of osteonecrosis of the femoral head.</article-title><source>Orthop Rev</source><year>1994</year><volume>23</volume><fpage>487</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">8065806</pub-id></element-citation></ref><ref id="CIT0020"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegmund</surname><given-names>W</given-names></name><name><surname>Ludwig</surname><given-names>K</given-names></name><name><surname>Giessmann</surname><given-names>T</given-names></name><name><surname>Dazert</surname><given-names>P</given-names></name><name><surname>Schroeder</surname><given-names>E</given-names></name><name><surname>Sperker</surname><given-names>B</given-names></name><etal/></person-group><article-title>The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.</article-title><source>Clin Pharmacol Ther</source><year>2002</year><volume>72</volume><fpage>572</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">12426521</pub-id></element-citation></ref><ref id="CIT0021"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegsmund</surname><given-names>M</given-names></name><name><surname>Brinkmann</surname><given-names>U</given-names></name><name><surname>Schaffeler</surname><given-names>E</given-names></name><name><surname>Weirich</surname><given-names>G</given-names></name><name><surname>Schwab</surname><given-names>M</given-names></name><name><surname>Eichelbaum</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors.</article-title><source>J Am Soc Nephrol</source><year>2002</year><volume>13</volume><fpage>1847</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">12089380</pub-id></element-citation></ref><ref id="CIT0022"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugano</surname><given-names>N</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Ohzono</surname><given-names>K</given-names></name><name><surname>Kubo</surname><given-names>T</given-names></name><name><surname>Hotokebuchi</surname><given-names>T</given-names></name><name><surname>Takaoka</surname><given-names>K.</given-names></name></person-group><article-title>The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head.</article-title><source>J Orthop Sci</source><year>2002</year><volume>7</volume><fpage>601</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12355139</pub-id></element-citation></ref><ref id="CIT0023"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanabe</surname><given-names>M</given-names></name><name><surname>Ieiri</surname><given-names>I</given-names></name><name><surname>Nagata</surname><given-names>N</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Kanamori</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene.</article-title><source>J Pharmacol Exp Ther</source><year>2001</year><volume>297</volume><fpage>1137</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">11356939</pub-id></element-citation></ref><ref id="CIT0024"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thervet</surname><given-names>E</given-names></name><name><surname>Anglicheau</surname><given-names>D</given-names></name><name><surname>King</surname><given-names>B</given-names></name><name><surname>Schlageter</surname><given-names>MH</given-names></name><name><surname>Cassinat</surname><given-names>B</given-names></name><name><surname>Beaune</surname><given-names>P</given-names></name><etal/></person-group><article-title>Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.</article-title><source>Transplantation</source><year>2003</year><volume>76</volume><fpage>1233</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">14578760</pub-id></element-citation></ref><ref id="CIT0025"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuji</surname><given-names>A</given-names></name><name><surname>Sakata</surname><given-names>I</given-names></name><name><surname>Tamai</surname><given-names>I.</given-names></name></person-group><article-title>Tissue distribution of the mdr gene product PGP and its physiological function.</article-title><source>Nippon Rinsho</source><year>1997</year><volume>55</volume><fpage>1059</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">9155153</pub-id></element-citation></ref><ref id="CIT0026"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsujimura</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Nakayamada</surname><given-names>S</given-names></name><name><surname>Nakano</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus.</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><fpage>1676</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">15934077</pub-id></element-citation></ref><ref id="CIT0027"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Ahsen</surname><given-names>N</given-names></name><name><surname>Richter</surname><given-names>M</given-names></name><name><surname>Grupp</surname><given-names>C</given-names></name><name><surname>Ringe</surname><given-names>B</given-names></name><name><surname>Oellerich</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>VW.</given-names></name></person-group><article-title>No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients.</article-title><source>Clin Chem</source><year>2001</year><volume>47</volume><fpage>1048</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11375290</pub-id></element-citation></ref><ref id="CIT0028"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray.</article-title><source>Genet Test</source><year>2004</year><volume>8</volume><fpage>411</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15684873</pub-id></element-citation></ref><ref id="CIT0029"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>CR</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Gaber</surname><given-names>AO</given-names></name><name><surname>Kotb</surname><given-names>M</given-names></name><etal/></person-group><article-title>The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.</article-title><source>J Clin Pharmacol</source><year>2003</year><volume>43</volume><fpage>555</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">12817518</pub-id></element-citation></ref></ref-list></back></article>